Article Text

Download PDFPDF

4CPS-188 Quality of life in patients on galcanezumab long-term treatment
  1. CM Dominguez-Santana1,
  2. E Rios-Sanchez2,
  3. EM Barreiro-Fernandez1,
  4. MA Blanco-Castaño1,
  5. JM Borrero-Rubio1
  1. 1Hospital Universitario Puerto Real, Farmacia, Puerto Real, Spain
  2. 2Hospital Universitario Puerto Real, Farmacia, Puerto Real Cádiz, Spain


Background and Importance Galcanezumab is a drug indicated for migraine prophylaxis. People with migraine experience significant functional and quality of life (QoL) impairment. Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1 was developed to address physical and emotional limitations.

Aim and Objectives To assess changes in long term QoL in patients treated with Galcanezumab.

Material and Methods Descriptive study of patients who received Galcanezumab (February 2020 to August 2022). QoL data were collected from patients at weeks 0, 4, 12 and 48 and from the electronic clinical history: sex, age, type of migraine, number of monthly migraine headache days (MHD) prior to treatment and duration of treatment. To assess effectiveness was used MSQv2.1(14-item questionnaire that measures QoL impacts in 3 domains: Role Function-Restrictive (RFR), measures limitations in social and work activities; Role Function-Preventive (RFP), measure the impact through prevention of these activities; and Emotional-Function (EF), assess the emotional impact. Higher scores indicate better QoL). The main variable was the rate of responders according to RFR defined as patients whose average change from baseline was ≥25 over week 48. Secondary outcomes were responders according RFR over week 4 and 12, and mean changes from baseline in RFR, RFP, EF and MSQ-total at weeks 4, 12 and 48.

Results 34 patients were included, 33 woman, mean age 45 years (29-69). Type of migraine: 70,5% chronic migraine and 29,5% high frequency episodic migraine. Mean monthly MHD prior to treatment were 18 days (8-30) and mean duration of treatment of 15 (3-27) months. 8 patients did not reach 48 weeks, treatment was discontinued for ineffectiveness. Main outcome: the rate of responders was 38,2% at week 48. Secondary outcomes: 34,2% and 45,7% responders at week 4 and 12 respectively. The table shows average change from baseline score in MSQ-domains and MSQ-total:

Conclusion and Relevance In this study, long-term galcanezumab treatment had a moderate effectiveness in improving the RFR-domain of QoL. The number of responders decreased over time. All domains improved from baseline over the weeks studied. However, at week 48, quality of life worsened compared to weeks 4 and 12.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.